Tammy Lee


Recombinetics Inc.




After initially joining Recombinetics in 2016 as corporate affairs chief, Tammy Lee took over as CEO in 2017 just as the emerging gene-editing company was working on a $34 million Series A funding, led by Gundersen Health System of La Crosse, Wisconsin. Now Lee—with deep experience in senior leadership at Carlson Cos., Delta Air Lines, Northwest Airlines, and other big corporate players—is trying her hand at guiding a biotech startup in the rapidly commercializing fields of regenerative medicine and genomics-based animal health. Both Lee and the company have strong connections to the University of Minnesota, creating strong opportunities for synergies.